Cardiac death prevention in post-myocardial infarction patients: a review.
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D003331:Coronary Vessels / Q000473:pathology; D003645:Death, Sudden / Q000209:etiology; D004195:Disease Models, Animal; D004285:Dogs; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D012008:Recurrence; D013442:Sulfinpyrazone / Q000627:therapeutic use; D014693:Ventricular Fibrillation / Q000209:etiology
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D004967:Estrogens; D000960:Hypolipidemic Agents; D001241:Aspirin; D013442:Sulfinpyrazone